Clinical Scorecard: Ethylenediaminetetraacetic Acid Potentiates the Efficacy of Vancomycin and Reactive Oxygen Species Against Vancomycin-Intermediate Staphylococcus aureus
VISA metabolic adaptations including downregulation of Krebs cycle enzymes promoting anaerobic metabolism, reducing ROS-mediated killing; EDTA potentiates ROS production enhancing vancomycin efficacy
Target Population
Patients with infections caused by VISA strains, particularly those refractory to vancomycin monotherapy
Care Setting
Hospital and clinical settings managing complicated MRSA and VISA infections
Key Highlights
VISA strains exhibit metabolic reprogramming that reduces susceptibility to vancomycin and innate immune ROS killing.
EDTA enhances vancomycin activity by increasing ROS-mediated bacterial killing both in vitro and in vivo.
Standard susceptibility testing in nutrient-rich media may underestimate VISA resistance due to lack of physiological condition simulation.
Guideline-Based Recommendations
Diagnosis
Consider physiological media testing to better detect VISA phenotypes not apparent in standard CA-MHB susceptibility assays.
Management
Adjunctive use of EDTA with vancomycin may improve treatment efficacy against VISA infections.
Monitor for potential enhanced bacterial killing via ROS mechanisms when combining EDTA with vancomycin.
Monitoring & Follow-up
Assess bacterial susceptibility under physiological conditions to guide therapy adjustments.
Monitor patient response to combination therapy for improved clearance of VISA.
Risks
Potential unknown effects of EDTA adjunctive therapy require further clinical evaluation.
Standard monotherapy with vancomycin may fail due to VISA metabolic adaptations.
Patient & Prescribing Data
Patients infected with vancomycin-intermediate Staphylococcus aureus strains exhibiting antibiotic tolerance
Combination therapy with EDTA and vancomycin enhances bacterial killing by promoting ROS susceptibility, potentially overcoming VISA resistance mechanisms.
Clinical Best Practices
Use physiological condition-based susceptibility testing to better identify VISA and guide therapy.
Consider EDTA as an adjunct to vancomycin in refractory VISA infections to potentiate ROS-mediated killing.
Recognize the metabolic adaptations of VISA that reduce antibiotic efficacy and tailor treatment accordingly.
